ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Recommendation of “Buy” by Brokerages

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has received an average recommendation of “Buy” from the ten ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $88.25.

ANIP has been the topic of several research analyst reports. Guggenheim lifted their price objective on ANI Pharmaceuticals from $86.00 to $114.00 and gave the company a “buy” rating in a research note on Monday. Truist Financial lifted their price objective on ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a “hold” rating in a research note on Monday, August 11th. Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 21st. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $93.00 price objective (up from $84.00) on shares of ANI Pharmaceuticals in a research note on Friday, August 8th.

ANI Pharmaceuticals Stock Up 3.4%

ANIP opened at $98.46 on Wednesday. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96. The stock has a market capitalization of $2.14 billion, a price-to-earnings ratio of -127.87 and a beta of 0.63. The business has a 50-day moving average of $77.56 and a two-hundred day moving average of $68.83. ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $98.49.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.42 by $0.38. The company had revenue of $211.37 million during the quarter, compared to analysts’ expectations of $187.18 million. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The firm’s revenue was up 53.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.02 EPS. On average, research analysts expect that ANI Pharmaceuticals will post 3.86 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $86.97, for a total value of $1,739,400.00. Following the transaction, the senior vice president directly owned 173,226 shares of the company’s stock, valued at $15,065,465.22. The trade was a 10.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Nikhil Lalwani sold 56,960 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $85.93, for a total value of $4,894,572.80. Following the transaction, the chief executive officer directly owned 411,219 shares in the company, valued at $35,336,048.67. This trade represents a 12.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 412,830 shares of company stock worth $36,382,434. 12.70% of the stock is owned by insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC lifted its position in ANI Pharmaceuticals by 89.3% during the 4th quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company’s stock worth $55,437,000 after acquiring an additional 473,097 shares in the last quarter. Global Alpha Capital Management Ltd. lifted its position in ANI Pharmaceuticals by 17.2% during the 2nd quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock worth $56,251,000 after acquiring an additional 126,500 shares in the last quarter. Deep Track Capital LP lifted its position in ANI Pharmaceuticals by 28.6% during the 4th quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company’s stock worth $35,879,000 after acquiring an additional 144,214 shares in the last quarter. Aberdeen Group plc lifted its position in ANI Pharmaceuticals by 76.1% during the 1st quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company’s stock worth $28,059,000 after acquiring an additional 181,134 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its position in ANI Pharmaceuticals by 14.6% during the 4th quarter. Ameriprise Financial Inc. now owns 271,805 shares of the specialty pharmaceutical company’s stock worth $15,025,000 after acquiring an additional 34,586 shares in the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.